Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H22N4O3 |
Molecular Weight | 354.403 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(CC2=C(N)N=C(N)N=C2)=C3C=C[C@@H](OC3=C1OC)C4CC4
InChI
InChIKey=HWJPWWYTGBZDEG-CQSZACIVSA-N
InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23)/t14-/m1/s1
Molecular Formula | C19H22N4O3 |
Molecular Weight | 354.403 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Aerie Pharmaceuticals, Inc. (Bridgewater, NJ), was developing a novel prostaglandin analog, AR-102, that had 150-fold greater selectivity and 30-fold greater potency at the FP receptor than latanoprost. In preclinical studies, the drug has shown greater IOP-lowering efficacy and alonger duration of action than latanoprost and betterocular tolerability than travoprost. AR-102 was in early-stage clinical development for glaucoma, which was discontinued later..
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Investigational treatments for postoperative surgical site infections. | 2007 Feb |
|
Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. | 2007 Sep 15 |
|
Current and novel antibiotics against resistant Gram-positive bacteria. | 2008 |
|
[New antimicrobials against Gram-positive organisms]. | 2008 |
|
Gateways to clinical trials. | 2008 Oct |
|
Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus. | 2009 |
|
Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus. | 2009 Aug |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00523250
AR-102 0.003-0.03% Ophthalmic Solution
Route of Administration:
Topical
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:11:27 GMT 2023
by
admin
on
Sat Dec 16 11:11:27 GMT 2023
|
Record UNII |
7P9VLC9Y9D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
44141864
Created by
admin on Sat Dec 16 11:11:27 GMT 2023 , Edited by admin on Sat Dec 16 11:11:27 GMT 2023
|
PRIMARY | |||
|
1208116-66-8
Created by
admin on Sat Dec 16 11:11:27 GMT 2023 , Edited by admin on Sat Dec 16 11:11:27 GMT 2023
|
PRIMARY | |||
|
7P9VLC9Y9D
Created by
admin on Sat Dec 16 11:11:27 GMT 2023 , Edited by admin on Sat Dec 16 11:11:27 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> ENANTIOMER |
|
||
|
RACEMATE -> ENANTIOMER |
|